Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A607338-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,334.90 | |
A607338-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,500.90 |
Synonyms | ABT-384|868623-40-9|4-[[2-methyl-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propanoyl]amino]adamantane-1-carboxamide|CHEMBL222670|ABT 384|R5TH77F919|SCHEMBL231595|UNII-R5TH77F919|ABT384|GTPL7357|CHEMBL4297256|SCHEMBL20457214|CLHMYBJIOZXCEX-MALZW |
---|---|
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | 11-beta-hydroxysteroid dehydrogenase 1 inhibitor |
ALogP | 2.6 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 4-[[2-methyl-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propanoyl]amino]adamantane-1-carboxamide |
---|---|
INCHI | InChI=1S/C25H34F3N5O2/c1-23(2,33-7-5-32(6-8-33)19-4-3-18(14-30-19)25(26,27)28)22(35)31-20-16-9-15-10-17(20)13-24(11-15,12-16)21(29)34/h3-4,14-17,20H,5-13H2,1-2H3,(H2,29,34)(H,31,35) |
InChi Key | CLHMYBJIOZXCEX-UHFFFAOYSA-N |
Canonical SMILES | O=C(C(N1CCN(CC1)c1ccc(cn1)C(F)(F)F)(C)C)NC1C2CC3CC1CC(C2)(C3)C(=O)N |
Isomeric SMILES | CC(C)(C(=O)NC1C2CC3CC1CC(C3)(C2)C(=O)N)N4CCN(CC4)C5=NC=C(C=C5)C(F)(F)F |
PubChem CID | 11670435 |
Molecular Weight | 493.6 |
PubChem CID | 11670435 |
---|---|
CAS Registry No. | 868623-40-9 |
Enter Lot Number to search for COA:
1. Sorensen B, Rohde J, Wang J, Fung S, Monzon K, Chiou W, Pan L, Deng X, Stolarik D, Frevert EU et al.. (2006) Adamantane 11-beta-HSD-1 inhibitors: Application of an isocyanide multicomponent reaction.. Bioorg Med Chem Lett, 16 (23): (5958-62). [PMID:16996734] |
2. An G, Liu W, Katz DA, Marek G, Awni W, Dutta S. (2013) Effect of ketoconazole on the pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study.. Drug Metab Dispos, 41 (5): (1035-45). [PMID:23431112] |
3. Katz DA, Liu W, Locke C, Jacobson P, Barnes DM, Basu R, An G, Rieser MJ, Daszkowski D, Groves F et al.. (2013) Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384.. Transl Psychiatry, 3 (3): (e295). [PMID:23982627] |
4. Marek GJ, Katz DA, Meier A, Greco 4th N, Zhang W, Liu W, Lenz RA. (2014) Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease.. Alzheimers Dement, 10 (5 Suppl): (S364-73). [PMID:24418055] |